Valsartan NDMA lawsuit MDL 2875: blood pressure medication contamination, $15.26 million class settlement, and the June 2 2026 claim deadline
If you took generic valsartan, losartan, or irbesartan for high blood pressure or heart failure between roughly 2011 and 2018, your pills may have contained trace amounts of N-nitrosodimethylamine (NDMA), N-nitrosodiethylamine (NDEA), or N-methyl-4-(nitrosomethylamino)butyric acid (NMBA). The first two are classified by the International Agency for Research on Cancer as Group 2A probable human carcinogens. NDMA in particular is a chemical you would not expect in a daily prescription medication; it appears in cured meats, tobacco smoke, and rocket fuel residue.
The contamination originated with a 2011 manufacturing process change at Zhejiang Huahai Pharmaceutical, a Chinese active pharmaceutical ingredient (API) supplier. The change went unnoticed for seven years. FDA caught it in July 2018 and began a cascading series of recalls that eventually covered generics from Hetero Drugs, Mylan (now Viatris), Teva, Solco Healthcare, Torrent, Aurobindo, and Vivimed.
Most of the federal personal injury and economic loss claims were consolidated into MDL 2875 (In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation, Case No. 1:19-md-02875-RBK-SAK) on February 14, 2019. The MDL sits in the District of New Jersey before Chief Judge Renee M. Bumb. As of March 2026, 1,418 personal injury cases are active; 1,588 have been filed across the MDL's lifetime.
What plaintiffs are alleging
The substantive theory is straightforward. Generic manufacturers used production processes that generated nitrosamine impurities at levels above what FDA considers safe for chronic exposure. Patients took the contaminated pills daily for years. NDMA exposure at chronic doses is associated in animal and epidemiological studies with cancers of the liver, stomach, colon and rectum, kidneys, pancreas, and bladder. The plaintiffs developed those cancers.
Defendants dispute the causation chain at every link: dose levels, latency, individual cancer risk factors, and whether plaintiffs can prove they took the specific contaminated lots rather than clean ones from the same manufacturer.
The $15.26 million economic loss settlement
In February 2026, Judge Bumb preliminarily approved three separate economic loss class settlements totaling $15.26 million:
- Hetero Valsartan: $11.37 million (covers consumers and insurers who paid for valsartan manufactured using Hetero Process III API, sold under the Camber Pharmaceuticals label between May 1 and July 31, 2018)
- Aurobindo Irbesartan: $2 million
- Vivimed Losartan: $1.9 million
These settlements are economic loss only. They reimburse the price you (or your insurer) paid for medication that allegedly should not have been on the market. They do not cover personal injury, medical expenses, or pain and suffering. Those claims continue separately on the personal injury track.
The claim deadline is June 2, 2026. The final approval hearing is scheduled for June 30, 2026. Claims are submitted through the court-authorized site at SartanMedicationSettlement.com.
The personal injury track
The 1,418 active personal injury cases are still in pretrial. The first bellwether trial was scheduled for October 2025, and Judge Bumb has asked attorneys to prepare for a second round. Bellwether outcomes typically drive global settlement negotiations in pharmaceutical MDLs of this size: once a handful of representative cases have been tried, both sides have data on what juries will award for different injury patterns, and the remaining cases tend to resolve in that shadow.
No global personal injury settlement has been announced as of early 2026, and the parties expect serious settlement discussions only after bellwether verdicts.
Defendants include Zhejiang Huahai (China, primary API manufacturer), Hetero Drugs (India), Mylan/Viatris, Teva, Solco Healthcare, Torrent, Aurobindo, and Vivimed.
What documentation matters
Two pieces of evidence carry most of the weight in any individual case.
Manufacturer identification. A "valsartan prescription" is not enough. The case turns on whether you took pills from one of the contaminated manufacturers during the contamination window. Pharmacy records show the NDC (National Drug Code) for every fill, and the NDC identifies the manufacturer. Every U.S. pharmacy is required to retain prescription records for at least two years (most keep them seven to ten); insurance carriers keep claim histories that include NDC codes for similar periods. Request a manufacturer-specific prescription history from every pharmacy you used during the relevant years.
Cancer diagnosis with documented causation analysis. Pathology reports, imaging (CT, MRI, PET), staging documentation, and a treating oncologist who is willing to address latency and exposure are the foundation. The cancer types most commonly alleged are liver, gastric, colorectal, kidney, pancreatic, and bladder. Cancer at sites that have no plausible mechanism for NDMA exposure (skin, brain, hematological) are harder to fit into the causation theory.
Statute of limitations
Most states give you two to four years from the date you knew or reasonably should have known your cancer was linked to the medication. The discovery rule applies in most jurisdictions, which means the clock generally starts at the point a reasonable person would have connected the dots, not the date you took the pill. The FDA recalls in 2018 and 2019 are often treated as the constructive notice point in motion practice. Specific state law analysis is required; some states (Tennessee, Louisiana) are notably shorter than others.
If you have a confirmed cancer diagnosis and any plausible exposure history, the safe move is to consult counsel rather than wait. The statute does not extend automatically because a class settlement was pending.
Tax treatment of any eventual recovery
Personal injury settlements for physical injuries are excluded from gross income under IRC §104(a)(2). Component allocation matters: portions of a settlement attributed to emotional distress (not arising from physical injury), punitive damages, or interest are generally taxable. If a settlement is large enough to substantially change your tax bracket or your retirement planning, coordinate the allocation with tax counsel before signing.
For plaintiffs accessing retirement accounts to cover medical expenses during pretrial, the §72(t) early withdrawal penalty framework includes a medical expense exception that may reduce the 10% additional tax.
How this fits with other NDMA litigation
Valsartan is the second major NDMA-contamination mass tort after Zantac (ranitidine), which followed a similar arc: long-term consumer use, NDMA discovered as a degradation product, FDA action in 2019-2020, and a sprawling MDL. The Zantac MDL was substantially dismantled at the Daubert stage in the federal court but state court litigation has continued. The Valsartan MDL has survived its analogous Daubert challenges so far, which is part of why bellwether trials are proceeding rather than the case being unwound.
The two litigations are not formally linked but the science overlaps; rulings on NDMA dose-response and causation in one have been cited in the other.
Practical next steps
If you have records of taking generic valsartan, losartan, or irbesartan between roughly 2011 and 2018 but have not been diagnosed with cancer, the economic loss class settlement is the relevant track. The claim form takes under thirty minutes if you have pharmacy receipts or insurance records, and the June 2 deadline is firm.
If you have been diagnosed with one of the alleged cancer types and have a documented exposure history, the personal injury track is a separate analysis. Consult counsel experienced with MDL 2875 before the bellwether outcomes start moving settlement values; case intake terms shift after major verdicts.
If you are unsure whether you took an affected product, start with pharmacy records. The NDC codes on your fill history are the dispositive piece of evidence, and they are usually retrievable for the cost of a request. FDA maintains a running list of recalled angiotensin II receptor blocker (ARB) products sortable by manufacturer and NDC.
The contaminated lots are no longer on the U.S. market; manufacturers have implemented testing protocols that catch nitrosamine impurities at much lower thresholds than were standard before 2018. The litigation is about what happened during the seven-year window when the contamination went undetected, and the deadlines for class participation and personal injury filing are running now.